XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
  Memory
  Regeneration
  Stroke
  Brain Diseases
  Headache
  Spinal Cord Diseases
  Demyelinating Diseases
  Neurodegenerative Diseases
  Taste
  Trigeminal Neuralgia
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Warfarin versus Aspirin for Symptomatic Intracranial Disease (WASID) trial

Stroke Channel
subscribe to Stroke newsletter

Latest Research : Neurosciences : Stroke

   DISCUSS   |   EMAIL   |   PRINT
WASID trial - Identifying patients most at-risk for a secondary stroke
Jan 28, 2006, 12:57, Reviewed by: Dr. Priya Saxena

"Stenting and angioplasty in the brain are promising treatments for intracranial stenosis, and this study identified the target group for a new trial comparing these treatments with traditional medical therapy."

 
Among patients who have suffered a single stroke, researchers at the University of Pennsylvania School of Medicine, along with colleagues at other institutions, have found that severe stenosis, or narrowing, of the arteries in the head represents a major risk factor for the development of a subsequent stroke. Patients with recent symptoms were also at high risk. Further, women faced a greater risk of subsequent stroke than men. Their work, to be published in the January 31 issue of Circulation, lays the foundation for further studies into effective therapies to prevent secondary strokes.

The researchers' findings are part of a larger multi-site clinical investigation - specifically, the Warfarin versus Aspirin for Symptomatic Intracranial Disease (WASID) trial - which found aspirin to be the preferred medical therapy for preventing a secondary stroke. According to the WASID study, warfarin was associated with significantly higher rates of adverse events and provided no benefit over aspirin for preventing stroke and vascular death.

The Penn study - which has now identified the patient-population that is most at-risk for a secondary stroke - sets the stage for additional studies to test more alternative treatments. "We need to be more aggressive in the treatment of these high-risk patients," said Scott Kasner, MD, lead author of the Circulation study and Director of Penn's Stroke Center. "Stenting and angioplasty in the brain are promising treatments for intracranial stenosis, and this study identified the target group for a new trial comparing these treatments with traditional medical therapy."

Using patient data from the WASID trial, Kasner's study analyzed five probable clinical factors that would contribute to a subsequent stroke in the territory of the initial event - including type of qualifying event (stroke or TIA), location of vessel, percent stenosis, treatment with antithrombotic medications at the time of the preliminary stroke, and time from the qualifying event to enrollment in the study. After adjusting for age, gender, and race, the researchers found that patients with severe stenosis (at or greater than 70% of the affected vessel's diameter), recent symptoms, and female gender were associated with significantly higher subsequent risk of stroke in the territory of a symptomatic intracrancial stenotic artery than other groups. "Our observations suggest that potential intervention should be considered very soon after clinical presentation, unless early intervention also increases the short-term risk," says Kasner.

"Intracranial stenting has not been evaluated in a controlled clinical trial and the effectiveness of this approach remains in question," adds Kasner.
 

- January 31 issue of Circulation
 

uphs.upenn.edu

 
Subscribe to Stroke Newsletter
E-mail Address:

 

This study was funded by a research grant from the US Public Health Service, NINDS.

For additional information on the evaluation of intracranial stenosis, contact Penn's Stroke Center at 215-662-4904.

PENN Medicine is a $2.7 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.

Penn's School of Medicine is ranked #2 in the nation for receipt of NIH research funds; and ranked #4 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

Penn Health System comprises: its flagship hospital, the Hospital of the University of Pennsylvania, consistently rated one of the nation's "Honor Roll" hospitals by U.S. News & World Report; Pennsylvania Hospital, the nation's first hospital; Penn Presbyterian Medical Center; a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home health care and hospice.


Related Stroke News

New Effort to Treat Stroke More Effectively
REGARDS Study: Stroke Symptoms Common Among General Population
Video game for stroke rehabilitation?
Internal body clock dictates timing of different types of stroke
Stroke Costs in US set to top $2 trillion dollars
Agratroban May Promote Opening Of Arteries Following Stroke
SPARCL Trial: Atorvastatin reduces recurrent stroke risk
Healthy Lifestyle Reduces Women's Stroke Risk
Wingspan Intra-Cranial Stent, Alternative to Brain Surgery?
Blood pressure variability increases risk for stroke death


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us